Receptor News and Research

RSS

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

Columbia University has decided to award the Louisa Gross Horwitz Prize 2018.

24 Sep 2018

Researchers propose mechanism by which ASTN2 protein defects lead to brain disorders

In the brain, as in business, connections are everything. To maintain cellular associates, the outer surface of a neuron, its membrane, must express particular proteins--proverbial hands that reach out and greet nearby cells. And, like a creepily long handshake, surface molecules can overstay their welcome: A protein that lingers too long on the membrane may compromise the connections, or synapses, between cells.

24 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

New federally-funded research project could lead to treatments that extend human lifespan

A new federally-funded research project at the Ohio University Edison Biotechnology Institute and Heritage College of Osteopathic Medicine could lead to treatments that extend human lifespan and allow people to enjoy better health in their old age.

21 Sep 2018

Study: Neural signal that urges to eat overpowers the one that says to stop

Almost everyone knows the feeling. You're at a restaurant or a holiday meal, and your stomach is telling you it's full, so logically you know you should stop eating.

21 Sep 2018

Study reveals new way to target HER2-negative metastatic breast cancer

A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

20 Sep 2018

Genetic polymorphisms linked with muscle injury and stiffness

To test whether sex-related genetic polymorphisms are associated with muscle injury and stiffness, Noriyuki Fuku from Juntendo University and colleagues report in the journal Medicine & Science in Sports & Exercise that ESR1 rs2234693 polymorphism is associated with both muscle injury and muscle stiffness.

20 Sep 2018

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer.

19 Sep 2018

Researchers use larval zebrafish model to reveal role of locus coeruleus in anesthesia

The application of general anesthesia in clinical therapy has been an indispensable part of modern medicine for more than a century. However, due to the complexity of the brain and the extensive actions of general anesthetic drugs, neural mechanisms underlying general anesthesia have remained a mystery.

19 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Receptor News and Research

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

Researchers propose mechanism by which ASTN2 protein defects lead to brain disorders

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

New federally-funded research project could lead to treatments that extend human lifespan

Study: Neural signal that urges to eat overpowers the one that says to stop

Study reveals new way to target HER2-negative metastatic breast cancer

Genetic polymorphisms linked with muscle injury and stiffness

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

Researchers use larval zebrafish model to reveal role of locus coeruleus in anesthesia

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Surprising research showing peptide adaptability may pave way to develop immunotherapies

Sandalwood mimicking odorant could stimulate hair growth in humans

Machine learning program could distinguish between two lung cancer types

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Study: Children with acute lymphoblastic leukemia are immunologically disparate at birth

New project aims to increase patient willingness to take life-saving oral drugs

New statement provides detailed overview of how to diagnose, treat resistant hypertension

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News